Biotech · Private company
ExCellThera inc.
Track this companyFree. Adds ExCellThera inc. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- ECT-001-CB (UM171-Expanded Cord Blood Transplant)Phase 2 · High Risk Hematological MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- ECT-001-CB (UM171-Expanded Cord Blood Transplant)Phase 2 · High Risk Myeloid MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- ECT-001-CB (UM171-Expanded Cord Blood Transplant)Phase 1 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid MalignanciesPHASE1_PHASE2 · COMPLETED · started Dec 1, 2021ClinicalTrials.gov NCT04990323 · fetched Nov 12, 2026
- US Phase I Study of ECT-001-CB in Patients With Sickle-Cell DiseasePHASE1 · WITHDRAWN · started Jul 13, 2021ClinicalTrials.gov NCT04594031 · fetched Nov 12, 2026
- US Study of UM171-Expanded CB in Patients With High Risk Leukemia/MyelodysplasiaPHASE2 · COMPLETED · started Nov 13, 2020ClinicalTrials.gov NCT04103879 · fetched Nov 12, 2026